CD19 and congenital rubella syndrome: Among the 4 evaluable patients, 2 received CR, 1 received PR, and 1 had SD; (2) 19 CLL patients received CD19-targeted CAR T cells treatment, of which 18 patients developed CRS; Among the 18 subjects, 15 had grades 1-2, and 5 developed neurotoxicity.